GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Journal of Hematology & Oncology, Springer Science and Business Media LLC, Vol. 6, No. 1 ( 2013-12)
    Type of Medium: Online Resource
    ISSN: 1756-8722
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2013
    detail.hit.zdb_id: 2429631-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Elsevier BV ; 2010
    In:  Leukemia Research Vol. 34, No. 8 ( 2010-08), p. e190-e193
    In: Leukemia Research, Elsevier BV, Vol. 34, No. 8 ( 2010-08), p. e190-e193
    Type of Medium: Online Resource
    ISSN: 0145-2126
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2010
    detail.hit.zdb_id: 2008028-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Annals of Hematology, Springer Science and Business Media LLC, Vol. 102, No. 1 ( 2023-01), p. 89-97
    Type of Medium: Online Resource
    ISSN: 0939-5555 , 1432-0584
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2023
    detail.hit.zdb_id: 1458429-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Annals of Hematology, Springer Science and Business Media LLC, Vol. 93, No. 10 ( 2014-10), p. 1685-1694
    Type of Medium: Online Resource
    ISSN: 0939-5555 , 1432-0584
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2014
    detail.hit.zdb_id: 1458429-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Blood, American Society of Hematology, Vol. 106, No. 11 ( 2005-11-16), p. 4226-4226
    Abstract: Objectives In previous study, we have successfully established a murine marrow-derived multipotent stem cell line (mMMSC) from male C57BL/6 mice with highly proliferation and multipotency, which could differentiate into cells of three germ layers in vitro, such as adipocytes, osteoblasts, endothelium cells, hepatocytes and neutral cells, but not hematopoietic cells. The mMMSC expressed high levels of CD29, CD44 and Sca-1, low levels of CD13, CD90, Flk-1 and MHC-I, while negative for CD117, CD45 and MHC-II. RT-PCR showed that two transcription factors important in maintaining undifferentiated embryonic stem cell (ES), Oct-4 and Rex-1, were expressed. The present study was aimed at developing a mMMSC transplantation animal model to evaluate its role in hematopoietic reconstitution. Methods mMMSC and bone marrow cells (BM) freshly harvested from male C57BL/6 mice were used as donor cells. Female C57BL/6 mice lethally irradiated for 8Gy (25cGy/min) with 60Co were used as recipients, which were randomly defined into 4 groups: Group A (Control, n=5) were injected with 0.2ml PBS/per mouse within 4–6 hours after irradiation (injection timepoint was similar thereafter); Group B (BM, n=5): 0.2ml of 6×106 donor BM cells/per mouse; Group C (mMMSC, n=10): 0.2ml of 2×106 mMMSC/per mouse; Group D(mMMSC+BM, n=5): 0.2ml of 2×106mMMSC+6×106 BM cells /per mouse. The fluctuations of WBC and PLT in peripheral blood (PB) were evaluated every week until day 42 after transplantation. At day 42 post-transplantation, all alive mice were sacrificed for histological examination, chromosome analysis with R-banding, FISH using murine chromosome Y painting probe and sex-determining region of Y chromosome(sry) gene analysis with PCR. Results After irradiation, all mice in control group died of bone marrow failure between day 14 and 17. WBC and Hb recovered to (4.03±0.61)×109/L and (127.33±24.00)g/L at day 21 and PLT recovered to (812.33±67.38)×109/L at day 28 post-transplantation in mMMSC group. WBC and PLT in mMMSC group were lower than that in BM and mMMSC+BM groups on days 14 and 21 (P & lt;0.05), and recovered to the same level on day 28, without significant difference among the above 3 groups thereafter. The recovery of WBC and PLT count in mMMSC+BM group was faster than that of BM group (P & lt;0.05). In groups B,C and D, sry gene was detectable in BM, PB and spleen. Y chromosome was found in 100±0%, 50±5% and 100±0% of BM nucleated cells by conventional chromosomal analysis, and Y-positive signals were detected by FISH in 90.67±1.46%, 45.03±1.11% and 94.82±0.90% of interphase nuclei and metaphases, respectively. Highly purified CD45+cells sorted with MACS from BM and PB of mMMSC group showed Y chromosome in 33.3±11.55% of CD45+ BM cells by karyotyping. FISH ascertained Y chromosome in 31.18±1.83% and 24.65±2.77% of CD45+ cells from BM and PB, respectively. Conclusions 1.mMMSC transplantation alone can successfully reconstitute hematopoiesis in lethally irradiated mice. mMMSC can differentiate into hematopoietic cells in vivo and thus might be used as a novel substitute for hematopoietic stem cells (HSC). 2. Co-transplantation of mMMSC and HSC can enhancing hematopoietic reconstitution, which could be one of the potential strategies to use mMMSC for transplantation purposes.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2005
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Blood, American Society of Hematology, Vol. 122, No. 21 ( 2013-11-15), p. 1379-1379
    Abstract: Acute myeloid leukemia (AML) is a clonal hematologic malignancy arising from a small population of leukemic cells that initiate and propagate the disease. These cells are termed leukemic stem cells (LSCs), which are found within the CD34+CD38- cell compartment. The LICs subpopulation survives chemotherapy and is most probable the cause of minimal residual disease (MRD), which in turn is thought to cause relapse. The aim of this study was to determine the prognostic value of the percentage of LICs measured by fluorescence in situ hybridization (FISH) in flow sorted CD34+CD38- cells (FISH+CD34+CD38- population) at diagnosis. Forty-five patients with de novo AML with FISH-detectable cytogenetic abnormalities treated with CHAML 2010 protocol were retrospectively included in this study. The last follow-up was March 31, 2013, and the median follow-up for patients was 12 months (range: 1–27 months). After 24 months, 12 patients (26.7%) had experienced relapse, whereas 7 patients (17.9%) had died due to non-relapse treatment-related complications, 3 from treatment-related complications of transplantation and 4 from infection after chemotherapy. To distinguish normal and leukemic cells within the CD34+CD38- cell compartment, we established a unique protocol for conducting FISH on flow-sorted cells. The FISH positive percentage at diagnosis constituting an average of 2.31% (range: 0.01%-29.4%) of the blast cells and 68.2% (range: 7.8%-89.6%) of the CD34+CD38- cells. According to the LIC level detected by Flow-FISH analysis, patients were categorized into the two groups: low LIC load (<1%) and high LIC load (≥1%), representing 44.4% (n=20) and 55.6% (n=25) of all patients, respectively. Comparison of clinical and laboratory characteristics showed no significant differences between two groups in age, gender, white blood cell (WBC) count, platelet (PLT) count, blast percentage, FAB subtype distribution, FLT3 mutation status and cytogenetics risk at diagnosis. High LIC load at diagnosis was significantly correlated with increased risk of poor clinical outcome. The 2-year overall survival (OS) for patients with low LIC load was 0.7257[0.4082, 0.8916] , compared with 0.1675[0.0323, 0.3947] for the patients with high LIC load (P=0.0004). And 2-year events-free survival (EFS) were 0.6723[0.3262, 0.8687] versus 0.1633[0.0328, 0.3825], respectively (P=0.0029). By multivariate analysis, high LIC load retained prognostic significance for OS and EFS. Furthermore, high LIC load at diagnosis was found to be significantly associated with elevated cumulative incidence of relapse (2-year CIR: 56.7% vs. 18.0%; P = 0.021). In summary, our study established the Flow-FISH protocol as a useful method to distinguish normal and leukemic cells within the CD34+CD38- cell subpopulation. And Flow-FISH might be easily adopted as a powerful tool to predict clinical outcome and help physicians to evaluate criteria for treatment in AML with recurrent cytogenetic abnormalities. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2013
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Blood, American Society of Hematology, Vol. 122, No. 21 ( 2013-11-15), p. 1356-1356
    Abstract: Acute myeloid leukemia (AML) is generally regarded as a stem cell disease, known as leukemic initiating cells (LIC), which initiate the disease and contribute to relapses. Although the phenotype of these cells remains unclear in most patients, they are enriched within CD34+CD38- compartment. In core binding factor (CBF) AML, the cytogenetic abnormablities are also existed in LIC. The aim of this study was to determine the prognostic power of minimal residual disease measured by fluorescence in situ hybridization (FISH) in flow sorted CD34+CD38- cells (FISH+CD34+CD38- population) at different period during the therapy. Thirty-six patients under 65 years of age with de novo CBF AML and treated with CHAML 2010 protocol were retrospectively included in this study. FISH efficiently identified the LICs (FISH+CD34+CD38-) in the CD34+CD38- population. The last follow-up was March 31, 2013, and the median follow-up was 336 days (range: 74-814 days). 33 patients with complete remission (CR) were eligible for the study, and 23 patients (23/33, 69.7%) with t (8;21) or AML1/ETO, and the remaining (10/33, 30.3%) with inv(16)/t(16;16) or CBFβ/MYH11. Flow-cytometry based FISH (F-FISH) procedure was performed at diagnosis, before every cycle of consolidation therapy, and every 3 months during follow-up. The FISH+ percentage at diagnosis constituting an average of 2.1% (range: 0.01%-27.5%) of the blast cells and 64.6% (range: 14%-87.8%) of the CD34+CD38- cells. Before the consolidation, FISH+CD34+CD38- population was detected in 13/33 (39.4%) patients. At this checkpoint, we have found the existence of FISH+CD34+CD38- population had prognostic value for the end points relapse free survival (RFS, 12% versus 68%, P=.008), and retained prognostic significance for RFS in multivariate analysis. Furthermore, the detection of FISH+CD34+CD38- before consolidation was found to be significantly associated with decreased OS. (11% versus 75%, P=.0005) Minimal residual disease (MRD) detected with F-FISH had a prognostic value at an earlier checkpoint when compared with flow cytometry and RT-PCR. Meanwhile, the concordance of flow cytomety, RT-PCR and F-FISH was investigated in the same patient cohort. 14 (70%) of 20 samples with detectable fusion transcripts by PCR did not have detectable leukemic cells by F-FISH. Therefore, the concordance for PCR and F-FISH was 63.7%. The concordance of FC and F-FISH was 64.3%: in 40 samples MRD was detected by both methods and in 61 samples MRD was ruled out by a negative result with the tests. With further analysis, the discrepancies among MRD detected with different MRD monitoring approaches before consolidation and after the first consolidation therapy contribute to 84% of the disconcordance. In summary, the detection of FISH+CD34+CD38- cells before consolidation therapy was significantly correlated with long-term survival in de novo CBF AML patients. F-FISH might be easily adopted as MRD monitor approach in clinical practice to identify patients at risk of treatment failure from the early stage during therapy. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2013
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...